NovoCure Ltd
NVCR Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$14.40
KIRA · Stoqly’s AI analyst, in plain words
- NovoCure Ltd had $655M of revenue in fiscal 2025, up 8.3% on the year before. Over five years, revenue changed +5.8% a year on average.
- Its operating margin was −23.5%, up 4.7 pts: of every 100 in sales, about −23 is left after running the business.
- NovoCure Ltd lost $136M in fiscal 2025.
- Free cash flow was −$75.7M in fiscal 2025, −11.5% of revenue.
- NovoCure Ltd owes $101M more than it holds in cash.
Market cap
$1.7B
P/E
—
Revenue
$655M
Net income
−$136M
Free cash flow
−$75.7M
Operating margin
−23.5%
NovoCure Ltd in 30 seconds · fiscal 2025
Are sales growing?
+8.3%
Yes. Sales grew 8.3% last year.
Does it make a profit?
−20.8%
No. It lost money last year.
Does profit turn into cash?
−11.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NovoCure Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- NovoCure Ltd
- CIK
- 0001645113
NovoCure Ltd · NVCR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $535M | $538M | $509M | $605M | $655M |
| Revenue growth | 8.2% | 0.5% | −5.3% | 18.8% | 8.3% |
| Net interest income | — | $7.7M | — | — | — |
| Gross margin | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating margin | −8.3% | −16.6% | −45.7% | −28.2% | −23.5% |
| Net income | −$58.4M | −$92.5M | −$207M | −$169M | −$136M |
| Net margin | −10.9% | −17.2% | −40.6% | −27.9% | −20.8% |
| Diluted EPS | −$0.56 | −$0.88 | −$1.95 | −$1.56 | −$1.22 |
| Cash | |||||
| Cash from operations | $82.8M | $30.8M | −$73.3M | −$26.4M | −$49.0M |
| Capital expenditure | $24.2M | $21.4M | $27.1M | $42.9M | $26.6M |
| Free cash flow | $58.6M | $9.4M | −$100M | −$69.2M | −$75.7M |
| FCF margin | 11.0% | 1.8% | −19.7% | −11.4% | −11.5% |
| Share count change | −5.0% | 1.2% | 1.7% | 1.4% | 3.4% |
| Debt and strength | |||||
| Cash and short-term investments | $209M | $115M | $241M | $164M | $93.5M |
| Debt incl. finance leases | $562M | $566M | $569M | $97.3M | $195M |
| Shareholders' equity | $410M | $441M | $362M | $360M | $340M |
| Current ratio | 7.5x | 7.0x | 5.8x | 1.5x | 2.9x |
| Interest coverage | −5.0x | −11.0x | −47.5x | −14.6x | −6.9x |
| Returns and quality | |||||
| Return on capital | −4.6% | −7.9% | −26.6% | −45.9% | −27.5% |
| Return on equity | −13.2% | −21.7% | −51.5% | −46.7% | −38.9% |
| Return on tangible equity | −14.2% | −21.0% | −57.1% | −46.8% | −40.0% |
| Piotroski F-score | 4 | 4 | 1 | 5 | 3 |
| Altman Z'' | 3.7 | 3.2 | 1.2 | −1.7 | −2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.3M
14 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NovoCure Ltd · NVCR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.40 a share, the company is worth $1.7B.
Source: SEC EDGAR XBRL filings (CIK 0001645113). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.